AbbVie has completed its acquisition of Cerevel Therapeutics for approximately $8.7 billion—strengthening its foundation in neuroscience and positioning itself to deliver sustainable long-term performance.
 
“Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie,” said Robert A. Michael, chief executive officer, AbbVie.
 
There are multiple programs in Cerevel’s pipeline across several neurological and psychiatric conditions such as schizophrenia, Parkinson’s disease and mood disorders, where there continues to be significant unmet need for patients. Cerevel’s pipeline is highly complementary to AbbVie’s existing neuroscience portfolio and the completion of the acquisition is an important step forward to delivering new and better tolerated therapies.
 
Cerevel’s pipeline includes:
 

• Emraclidine, a potential best-in-class, next-generation antipsychotic, is a positive allosteric modulator (PAM) of the muscarinic M4 receptor that is being studied for the treatment of schizophrenia.
• Tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of Parkinson’s disease.
• CVL-354, a potential best-in-class kappa opioid receptor (KOR) antagonist that has the potential to provide significantly improved efficacy and tolerability compared to existing treatments for major depressive disorder (MDD).

More Pharma Acquisitions